- Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease
-
Zhang XL, Wang TY, Targher G, Byrne CD, Zheng MH
- KMID: 2530178
- Diabetes Metab J.
- 2022 May;46(3):391-401.
- doi: 10.4093/dmj.2022.0048
Non-alcoholic fatty liver disease occurring in non-obese subjects (the so-called non-obese NAFLD) is a highly prevalent but neglected liver condition, which is closely associated with metabolic disorders and suboptimal lifestyles.... -
- CITED
-
- Close
- SHARE
-
- Close
- Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
-
Miao L, Xu J, Targher G, Byrne CD, Zheng MH
- KMID: 2534339
- Clin Mol Hepatol.
- 2022 Oct;28(4):725-738.
- doi: 10.3350/cmh.2022.0015
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity... -
- CITED
-
- Close
- SHARE
-
- Close
- Bioactive metabolites: A clue to the link between MASLD and CKD?
-
Chen WY, Zhang JH, Chen LL, Byrne CD, Targher G, Luo L, Ni Y, Zheng MH, Sun DQ
- KMID: 2563407
- Clin Mol Hepatol.
- 2025 Jan;31(1):56-73.
- doi: 10.3350/cmh.2024.0782
Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the... -
- CITED
-
- Close
- SHARE
-
- Close
